Table 3.

ORs (95% CIs) for the renal end pointa per doubling in plasma biomarker concentration in both cohorts

BiomarkerModel 1 OR (95% CI)Model 2 OR (95% CI)Model 3 OR (95% CI)
ACCORD
 TNFR-12.51 (1.68 to 3.77)2.82 (1.80 to 4.42)2.44 (1.48 to 4.04)
 TNFR-24.01 (2.29 to 7.01)4.22 (2.29 to 7.75)3.17 (1.65 to 6.08)
 KIM-11.99 (1.50 to 2.65)2.00 (1.49 to 2.70)2.42 (1.66 to 3.53)
VA-NEPHRON-D
 TNFR-12.28 (1.73 to 3.03)2.21 (1.6 to 3.06)2.38 (1.7 to 3.34)
 TNFR-22.20 (1.64 to 2.96)1.97 (1.41 to 2.75)1.98 (1.41 to 2.79)
 KIM-11.92 (1.64 to 2.24)1.83 (1.54 to 2.17)1.73 (1.45 to 2.06)
  • All ORs are for a continuous log2 change in biomarker levels. Model 1: individual biomarker only. Model 2: Model 1 + treatment arm, baseline eGFR, and albuminuria. Model 3: Model 2 + age, race, systolic blood pressure, diastolic blood pressure, and medications (fibrates/ACEis/ARBs).

  • a In ACCORD, renal end point is defined as achieving an eGFR<60 ml/min per 1.73 m2 along with a sustained (on two or more visits ≥3 months apart) decline in eGFR of ≥40% from baseline eGFR. In VA-NEPHRON-D, renal outcome is defined as the occurrence of a decline in the eGFR (an absolute decrease of ≥30 ml/min per 1.73 m2 if the eGFR was ≥60 ml/min per 1.73 m2 at randomization or a relative decrease of ≥50% if the eGFR was <60 ml/min per 1.73 m2) or ESRD (defined by the initiation of maintenance dialysis, receipt of kidney transplant, or an eGFR of <15 ml/min per 1.73 m2).